Unlocking the Potential of BCR(KLHL12) E3 Ubiquitin Ligase Complex as a Drug Target or Biomarker

Target Name: BCR(KLHL12) E3 ubiquitin ligase complex

NCBI ID: P18550

BCR(KLHL12) E3 ubiquitin ligase complex

Other Name(s): Cullin3-based E3 ubiquitin ligase complex

Unlocking the Potential of BCR(KLHL12) E3 Ubiquitin Ligase Complex as a Drug Target or Biomarker

Introduction

The BCR(KLHL12) E3 ubiquitin ligase complex is a protein-protein interaction (PPI) that plays a crucial role in the regulation of cellular processes such as cell division, apoptosis, and DNA damage repair. The discovery of this complex and its functions have increased interest in its potential as a drug target or biomarker. In this article, we will provide an overview of the BCR(KLHL12) E3 ubiquitin ligase complex, its functions, and potential as a drug target or biomarker.

Overview of the BCR(KLHL12) E3 Ubiquitin Ligase Complex

The BCR(KLHL12) E3 ubiquitin ligase complex is a protein complex composed of the BCR (Bcl2-Cullin3) protein, KLHL12 protein, and the E3 ubiquitin ligase enzyme. The BCR protein is a key adapter protein that links the ubiquitin arms to the target protein. The KLHL12 protein is a non-histone protein that plays a structural role in the complex. The E3 ubiquitin ligase enzyme is the active site for the ubiquitinylation of the target protein, which enables the ubiquitination of the target protein and its subsequent degradation.

Functions of the BCR(KLHL12) E3 Ubiquitin Ligase Complex

The BCR(KLHL12) E3 ubiquitin ligase complex plays a critical role in the regulation of cellular processes such as cell division, apoptosis, and DNA damage repair. One of its key functions is the regulation of cell division. During G1 phase, the BCR( KLHL12) E3 ubiquitin ligase complex promotes the ubiquitination and subsequent degradation of the protein p16INK4a, which is involved in cell cycle progression and apoptosis. This is important for ensuring that the cell divides properly and does not go into an uncontrolled cycle leading regulation to the formation of cancerous cells.

Another function of the BCR(KLHL12) E3 ubiquitin ligase complex is the regulation of apoptosis. The complex promotes the ubiquitination and subsequent degradation of the protein Bax, which is involved in cell apoptosis. Bax is a protein that plays a central role in the regulation of apoptosis, as it interacts with various cellular signaling pathways, including the Bcl-2 signaling pathway. The BCR(KLHL12) E3 ubiquitin ligase complex helps to ensure that Bax is properly targeted for degradation, which is necessary for proper cell death during apoptosis.

The BCR(KLHL12) E3 ubiquitin ligase complex also plays a role in DNA damage repair. When DNA is damaged, the complex helps to ensure that the damaged DNA is properly targeted for repair. The complex promotes the ubiquitination and subsequent degradation of the protein p53 , which is involved in the regulation of DNA damage repair. P53 is a protein that plays a critical role in ensuring that damaged DNA is properly repaired and that the cell is able to recover from the injury.

Potential as a Drug Target or Biomarker

The BCR(KLHL12) E3 ubiquitin ligase complex has great potential as a drug target or biomarker. Its functions in cell division, apoptosis, and DNA damage repair make it an attractive target for small molecules that can modulate these processes. Additionally, the complex's involvement in the regulation of Bax and P53 also suggests that it may be a useful target for drugs that are aimed at modulating these signaling pathways.

In recent years, several studies have investigated the BCR(KLHL12) E3 ubiquitin ligase complex as a drug

Protein Name: BCR(KLHL12) E3 Ubiquitin Ligase Complex

The "BCR(KLHL12) E3 ubiquitin ligase complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCR(KLHL12) E3 ubiquitin ligase complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets